Daily Markets -- Deltex Medical (LON:DEMG) , the AIM quoted medical device business, said this morning that the National Institute for Health and Clinical Excellence (NICE) had published final guidance recommending its CardioQ-ODM system. Deltex Medical is behind the development of systems that are used by clinicians for oesophageal Doppler monitoring (ODM). NICE, the body that guides the NHS on how and where to spend its money, issued preliminary guidance on Deltex Medical’s CardioQ-ODM in October 2010. That development triggered the start of a break out in the company’s share price, pulling it from around 12p to 17.75p. Today, the Deltex Medical share price soared by 46% to 29.25p.
